Valuation: Biocon Limited

Market Cap 599B 6.39B 5.76B 5.32B 4.81B 9.1B 9.32B 63.77B 25.41B 321B 23.98B 23.47B 1,021B P/E 2027 *
63.4x
P/E 2028 * 36.9x
Enterprise Value 704B 7.51B 6.77B 6.25B 5.65B 10.69B 10.96B 74.92B 29.86B 377B 28.18B 27.58B 1,200B EV / Sales 2027 *
3.69x
EV / Sales 2028 * 3.15x
Free-Float
51.72%
Yield 2027 *
0.15%
Yield 2028 * 0.23%
1 day-0.12%
1 week+6.85%
Current month+4.62%
1 month+5.34%
3 months-13.60%
6 months-5.74%
Current year-6.56%
1 week 357.35
Extreme 357.35
375.45
1 month 318.4
Extreme 318.4
375.45
Current year 318.4
Extreme 318.4
447.15
1 year 318.4
Extreme 318.4
447.15
3 years 224.35
Extreme 224.35
447.15
5 years 191.55
Extreme 191.55
447.15
10 years 139.37
Extreme 139.374999
487.75
Manager TitleAgeSince
Investor Relations Contact - -
Chief Executive Officer - 31/03/2026
Director of Finance/CFO 48 31/03/2026
Director TitleAgeSince
Director/Board Member 64 23/04/2014
Director/Board Member 71 31/12/1999
Chairman 73 28/11/1978
Change 5-day change 1-year change 3-year change Capi.($)
-0.12%+6.85%-4.43%+61.85% 6.4B
-1.06%-0.07%+60.76%+68.61% 68.32B
+1.30%+7.41%+14.79%+92.69% 60.26B
+0.39%+0.30%+20.04%+98.33% 55.86B
-0.95%+11.17%+22.21%+110.93% 48.43B
-0.23%+4.07%+25.63%+40.08% 45.34B
-6.40%-9.51%+181.99%+816.79% 41.76B
+1.97%+3.50%+25.78%+50.98% 34.5B
-0.56%-0.48%+85.57%+65.40% 33.8B
-0.82%-0.37%+45.38%-0.61% 25.96B
Average -0.64%+2.24%+47.77%+140.51% 42B
Weighted average by Cap. -0.64%+1.81%+49.76%+146.00%

Financials

2027 *2028 *
Net sales 191B 2.03B 1.83B 1.69B 1.53B 2.9B 2.97B 20.3B 8.09B 102B 7.63B 7.47B 325B 219B 2.34B 2.11B 1.95B 1.76B 3.33B 3.41B 23.35B 9.3B 118B 8.78B 8.59B 374B
Net income 9.26B 98.74M 88.99M 82.22M 74.33M 141M 144M 985M 393M 4.96B 371M 363M 15.78B 15.5B 165M 149M 138M 124M 235M 241M 1.65B 657M 8.3B 620M 607M 26.42B
Net Debt 105B 1.12B 1.01B 931M 841M 1.59B 1.63B 11.16B 4.45B 56.15B 4.2B 4.11B 179B 92.17B 983M 886M 818M 740M 1.4B 1.43B 9.81B 3.91B 49.37B 3.69B 3.61B 157B
Projected Income Statement - Annual - Biocon Limited
Logo Biocon Limited
Biocon Limited is an India-based biopharmaceutical company, engaged in the manufacture of biotechnology products and research services. The Company is in the business of manufacturing active pharmaceutical ingredients (APIs) and formulations, including biosimilar drugs for diabetics, oncology and autoimmune diseases. The Company’s segment includes Generics, Biosimilars, Novel Biologics and Research Services. It focuses on three key therapeutic areas - Oncology, Diabetes, and Immunology. Its APIs portfolio includes cardiovascular, anti-diabetics, immunosuppressants, and specialty molecules. Its products include Tacrolimus, Rosuvastatin, Simvastatin, Atorvastatin, Pravastatin, Fingolimod and others. Its APIs manufacturing facilities with capabilities in microbial fermentation, downstream process, including chromatographic purification, chemical synthesis, peptide synthesis and Highly Potent APIs (HPAPIs). It has over five facilities in Bangalore, Hyderabad and Visakhapatnam in India.
Employees
16,447
Date Price Change Volume
11/11/26 ₹368.05 -0.12% 2,883,367
09/11/26 ₹368.50 +0.34% 2,955,204
08/11/26 ₹367.25 +0.59% 482,922
06/11/26 ₹365.10 +0.86% 5,123,511
05/11/26 ₹362.00 +5.10% 6,787,308
Trader
Investor
Global
Quality
ESG MSCI
B
MarketScreener Ratings - Biocon Limited
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
368.05INR
Average target price
411.84INR
Spread / Average Target
+11.90%
  1. Stock Market
  2. Stocks
  3. BIOCON Stock